Boston Scientific’s EKOS System Outperforms Standard Care in Landmark Pulmonary Embolism Trial
Boston Scientific reported landmark clinical results today demonstrating that its EKOS Endovascular System significantly reduces complications in pulmonary embolism patients compared to the current standard of care. These findings, presented at the American College of Cardiology’s annual session, position the ultrasound-based technology as a potential first-line treatment and provide a clinical catalyst for a stock that has faced significant year-to-date pressure.
The global HI-PEITHO trial, which enrolled 544 patients, met its primary composite endpoint by showing a 61% reduction in clinical events for those treated with the EKOS system plus anticoagulation compared to anticoagulation alone. The data revealed a 4.0% event rate for the EKOS group versus 10.3% for the control group (P=0.005). Crucially, the intervention led to lower rates of cardiorespiratory collapse and shorter hospitalizations without increasing the risk of major bleeding or intracranial hemorrhage through 30 days.
For investors, these results validate Boston Scientific’s expansion into the pulmonary embolism (PE) market, which is expected to reach $6 billion globally by 2035. By proving superiority over traditional medical management, the EKOS system is well-positioned to capture a larger share of the intermediate-risk patient population—a segment previously managed conservatively due to the high bleeding risks associated with systemic clot-dissolving drugs. This data provides the clinical evidence required to shift hospital protocols toward interventional procedures.
This clinical victory arrives as Boston Scientific aggressively consolidates its vascular portfolio. Earlier this year, the company announced a $14.5 billion agreement to acquire Penumbra, a move aimed at establishing market leadership in thrombectomy against competitors like Inari Medical. The HI-PEITHO results provide a scientific "moat" for the EKOS system, ensuring it remains a competitive first-line option even as the company integrates Penumbra’s mechanical clot-removal technologies.
Despite the positive clinical news, BSX shares have struggled recently, trading at $69.17 with a year-to-date decline of 27.46%. The stock is currently trading just 4% above its 52-week low and remains below its major moving averages. However, technical indicators such as a 14-day RSI of 38.9 suggest the stock is approaching oversold territory. Wall Street sentiment remains largely bullish; in recent days, analysts at firms including Stifel and Jefferies have maintained Buy ratings, citing the potential for today’s ACC.26 trial readouts to serve as a turning point for the company's valuation.
BSX Stock Data
Key Takeaways
- The HI-PEITHO trial showed a 61% reduction in primary clinical events for the EKOS system compared to anticoagulation alone.
- The study demonstrated a strong safety profile with no reported brain bleeds, supporting a shift toward interventional first-line therapy for pulmonary embolism.
- The positive data reinforces Boston Scientific’s vascular growth strategy following its $14.5 billion acquisition of Penumbra earlier this year.